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Aims: The efﬁcacy of the once-daily prandial GLP-1 receptor agonist lixisenatide plus basal insulin in T2DM
was assessed by pooling results of phase III trials.
Methods: Ameta-analysis was performed of results from three trials in the GetGoal clinical program concerning
lixisenatide or placebo plus basal insulin with/without OADs. The primary endpoint was change in HbA1c from
baseline to week 24. Secondary endpoints were change in PPG, FPG, insulin dose, and weight from baseline to
week 24. Hypoglycemia rates and several composite endpoints were assessed.
Results: Lixisenatide plus basal insulin was signiﬁcantlymore effective than basal insulin alone at reducing HbA1c
at 24 weeks. Composite and secondary endpoints were improved signiﬁcantly with lixisenatide plus basal
insulin, with the exception of FPG, which showed no signiﬁcant difference between the groups. Lixisenatide plus
basal insulin was associated with an increased incidence of hypoglycemia versus basal insulin alone.
Conclusions: Lixisenatide plus basal insulin resulted in signiﬁcant improvement in glycemic control versus basal
insulin alone, particularly in terms of controlling PPG. Prandial lixisenatide in combination with basal insulin is a
suitable option for treatment intensiﬁcation in patients with T2DM insufﬁciently controlledwith basal insulin, as
these agents have complementary effects on PPG and FPG, respectively.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).ﬁ.
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Inc. This is an open access article u1. Introduction
Type 2 diabetes mellitus (T2DM) is a metabolic disorder
characterized by elevated blood glucose as a result of insulin
resistance and β-cell dysfunction. Early T2DM can be controlled
with lifestyle modiﬁcations and the use of oral antidiabetics (OADs)
(Garber, Abrahamson, Barzilay, et al., 2013; Ryden, Standl, Bartnik,
et al., 2007), while basal insulin as add-on to OADs is generally
initiated in patients with more advanced diabetes or in patients who
do not achieve glycemic control with OADs alone (American Diabetes
Association, 2013). Basal insulin once daily is effective for the control
of fasting plasma glucose (FPG); however, excursions in post-prandial
plasma glucose (PPG) in patients with poor glycemic control are not
addressed by basal insulin and may require prandial therapies. Basal–
bolus and basal-plus regimens, combining once-daily basal insulin
and mealtime administration of a rapid-acting insulin (RAI), or pre-
mixed insulin, are commonly recommended in this regard (Inzucchi,nder the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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particularly those with a prandial component (Holman, Farmer,
Davies, et al., 2009), are associated with weight gain and hypoglyce-
mia, which can impact patient acceptance of treatment (Cryer, Davis,
& Shamoon, 2003; Russell-Jones & Khan, 2007).
Incretin hormones secreted by the gastrointestinal tract stimulate
glucose-dependent insulin secretion to ensure that PPG excursions
are limited regardless of carbohydrate load (Holst, 2007; Crespo,
González Matías, Lozano, et al., 2009). The incretin glucagon-like
peptide-1 (GLP-1) is released post-prandially by the intestine but is
rapidly degraded by dipeptidyl peptidase-4 (DPP-4). The effects of
GLP-1 in the pancreas (release of insulin and suppression of glucagon
release) and in the stomach (delay of gastric emptying) have made
GLP-1 a focus of research for T2DM pharmacotherapies. A number of
GLP-1 receptor agonists (GLP-1 RAs) have been developed to take
advantage of the ‘incretin effect’. These agents include liraglutide and
exenatide once weekly (longer acting GLP-1 RAs with a predominant
effect on FPG), exenatide twice daily and lixisenatide (GLP-1 RAs with
a predominant effect on PPG). The clinical efﬁcacy of these agents in
T2DM is now established, and the advantage of signiﬁcant improve-
ments in glycemic control together with a low risk of hypoglycemia
and weight gain relative to other anti-diabetic agents has made GLP-1
RAs an attractive option for treatment intensiﬁcation.
Lixisenatide (Lyxumia®; Sanoﬁ, Paris, France) is a once-daily
prandial GLP-1 RA for the treatment of T2DM that is based on the
exendin-4 peptide with a glycine residue at position 2, prolonging its
activity as it is less readily degraded by DPP-4 (Werner, Haschke,
Herling, et al., 2010). Lixisenatide, as a monotherapy, in addition to
OADs or basal insulin, demonstrated signiﬁcant efﬁcacy versus
placebo in reducing glycated hemoglobin (HbA1c) and regulating
PPG with a beneﬁcial effect on body weight in the phase III GetGoal
clinical program (Ahrén, Leguizamo, Miossec, et al., 2013; Fonseca,
Alvarado-Ruiz, Raccah, et al., 2012; Riddle, Aronson, Home, et al.,
2013; Riddle, Forst, Aronson, et al., 2013; Seino, Min, Niemoeller, et al.,
2012). The PPG-lowering effects of prandial GLP-1 RAs, such as
lixisenatide, may be of particular beneﬁt for patients uncontrolled on
optimally titrated basal insulin, for whom PPG excursions are likely to
be the predominant contributor to hyperglycemia (Riddle, Umpierrez,
DiGenio, et al., 2011). Lixisenatide plus basal insulin versus basal
insulin alone, in patients whose T2DM was insufﬁciently controlled
with basal insulin or OADs, was assessed in three of the GetGoal trials
(GetGoal-Duo1, GetGoal-L and GetGoal-L-Asia); herein, we report a
meta-analysis of these trials in order to assess the efﬁcacy and safety
of lixisenatide plus basal insulin in a large and diverse patient
population. In doing so, we aim to provide information to guide
clinicians using lixisenatide in combination with basal insulin.
2. Materials and methods
2.1. Analysis design
This was a meta-analysis of data from patients with T2DM in the
three phase III GetGoal trials in which lixisenatide 20 μg once daily
was administered as add-on to basal insulin ± OADs and compared
with placebo plus basal insulin ± OADs. All medications were self-
administered according to the regimens of the individual trials.
The designs of these GetGoal trials have been reported previously
(Riddle, Aronson, Home, et al., 2013; Riddle, Forst, Aronson, et al.,
2013; Seino et al., 2012) (Supplementary Table 1). Brieﬂy, the
methodologies of these trials were as follows: GetGoal-Duo1
(NCT00975286) investigated lixisenatide as add-on to newly initiated
insulin glargine in patients whose T2DM was insufﬁciently controlled
with metformin ± thiazolidinediones; GetGoal-L (NCT00715624)
assessed lixisenatide as add-on to basal insulin in patients whose
T2DM was insufﬁciently controlled on basal insulin (insulin glargine,
insulin detemir or neutral protamine Hagedorn) ± metformin;GetGoal-L-Asia (NCT00866658) assessed lixisenatide as add-on to
basal insulin in Asian patients whose T2DM was insufﬁciently
controlled on basal insulin (insulin glargine, insulin detemir or
neutral protamine Hagedorn) ± sulfonylurea. Each of the trials was
of 24 weeks' duration and had change in HbA1c at trial end as the
primary endpoint. The trials were conducted between July 2008 and
August 2011 across 25 countries (the number of countries and
enrolment/completion dates varied by trial). Patients were random-
ized to receive lixisenatide or placebo 1:1 in GetGoal-Duo1 and
GetGoal-L-Asia, and 2:1 in GetGoal-L.
2.2. Inclusion criteria
All patients had inadequately controlled T2DM (HbA1c ≥7%) and
were randomized to receive either lixisenatide or placebo in addition
to treatmentwith basal insulin ± OADs in one of the phase III GetGoal
trials (thus three trials were included in this meta-analysis). Included
patients were from the intent-to-treat population of their respective
trial and were required to have HbA1c measurements at baseline and
at 24 weeks.
2.3. Endpoints
The primary endpoint of this meta-analysis (and of the three
GetGoal trials) was change in HbA1c from baseline to week 24.
Secondary endpoints included change from baseline in the proportion
of patients with HbA1c b7% or ≥7% at week 24. In addition, sub-
analyses were performed of HbA1c change from baseline to week 24 in
patients who were treated concomitantly with sulfonylureas versus
patients whowere not and in patients whowere basal-insulin naïve at
the beginning of treatment in the trials versus patients already
receiving basal insulin. Other secondary endpoints were the ﬁrst PPG
measurement after injection of lixisenatide based on patients' 7-point
self-monitored blood glucose proﬁles (mg/dL); 2-hour PPG levels
(mg/dL) after the standardizedmeal test; change from baseline in FPG
(mg/dL) at week 24; the proportion of patients with FPG b110 mg/dL
(6.1 mmol/L) or ≥110 mg/dL at week 24; and insulin dose (U/kg)
change at week 24. The standardized meal test consisted of a 600 kcal
liquid meal (400 mL Ensure Plus, Abbott Nutrition, Columbus, OH,
USA) comprising 53.8% carbohydrate, 16.7% protein and 29.5% fat, to
be consumed within a 10-minute period.
Safety endpoints in this meta-analysis were: prevalence of per-
protocol-deﬁned symptomatic hypoglycemia at week 24; the annu-
alized rate of symptomatic hypoglycemic events; and the number and
proportion of patients with severe hypoglycemia. A sub-analysis of
the occurrence of hypoglycemia was also performed in patients who
were being treated concomitantly with sulfonylureas versus patients
who were not. In common with trials of other GLP-1 RAs,
symptomatic hypoglycemia was deﬁned as an event with clinical
symptoms consistent with an hypoglycemic episode (e.g. sweating,
palpitations, hunger, fatigue, restlessness, anxiety, irritability, head-
ache, loss of concentration, somnolence, psychiatric or visual
disorders, transient sensory or motor defects, confusion, convulsions
or coma) with documented plasma glucose b60 mg/dL (3.3 mmol/L).
Severe hypoglycemia was deﬁned as an hypoglycemic event during
which patients required assistance from another person because they
could not self treat due to acute neurological impairment resulting
from hypoglycemia (The Diabetes Control & Complications Trial
Research Group, 1991) and where the event was associated with
plasma glucose b36 mg/dL (2.0 mmol/L) or where the event was
associated with prompt recovery after oral carbohydrate, or intrave-
nous glucose/glucagon.
This meta-analysis also assessed a number of composite endpoints
at week 24 that comprised both efﬁcacy and safety parameters; these
were: HbA1c levels b7% and no symptomatic hypoglycemia; HbA1c
Table 1
Baseline characteristics.
Characteristic Lixisenatide + basal
insulin (n = 665)
Placebo + basal
insulin (n = 533)
Mean age, years (SD) 57.4 (9.8) 56.9 (10.1)
Male, n (%) 306 (46.0) 268 (50.3)
Mean weight, kg (SD) 82.8 (21.2) 81.3 (21.2)
Mean BMI, kg/m2 30.6 (6.5) 30.0 (6.5)
Mean diabetes duration,
years (SD)
11.8 (7.1) 11.4 (7.0)
OAD use, n (%) 558 (83.9) 447 (83.9)
Metformina 485 (68.8) 353 (64.5)
Sulfonylureasa 108 (15.3) 111 (20.3)
Thiazolidinedionesa 27 (3.8) 27 (4.9)
Mean duration of OAD
use, years (SD)
6.3 (5.4) 5.9 (4.9)
Insulin use at
baseline, n (%)
437 (65.7) 306 (57.4)
Insulin use at
screening, n (%)
Insulin glargineb 260 (53.9) 175 (53.7)
Insulin detemirb 65 (13.5) 61 (18.7)
NPHb 152 (31.5) 85 (26.1)
Premix insulinb,c 5 (1.0) 5 (1.5)
Mean duration of
insulin use, years (SD)
2.0 (3.2) 1.9 (3.5)
Mean HbA1c, % (SD) 8.2 (0.9) 8.1 (0.8)
Mean FPG, mg/dL (SD) 134.4 (42.2) 133.2 (42.0)
BMI, body mass index; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; NPH,
neutral protamine Hagedorn; OAD, oral antidiabetic; SD, standard deviation.
a Safety population data for GetGoal-Duo1, GetGoal-L and GetGoal-L-Asia
(lixisenatide arm, n = 705; placebo arm, n = 547).
b Safety population data for GetGoal-L and GetGoal-L-Asia (lixisenatide arm, n = 482;
placebo arm, n = 326); patients fromGetGoal-Duo1are excluded as theywere insulin-naïve
at baseline.
c Patients receiving premix insulin at screening violated their respective study protocols.
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no symptomatic hypoglycemia.
2.4. Statistical methods
Descriptive statistics were used to measure and describe clinical
characteristics and patient demographic data, as well as to measure
and describe efﬁcacy and safety outcomes. The number of patients
and the associated percentage of the total number of patients with the
relevant data reported were determined for dichotomous variables.
The count, mean ± standard deviation (SD), and median were
reported for continuous variables. Treatment arms within each
group were compared with one another, with p-values calculated
using a chi-square test or analysis of variance test where appropriate.
A meta-analysis was used to determine the overall efﬁcacy and
safety of lixisenatide as an add-on treatment to basal insulin. Standard
meta-analytic techniques were applied to assess the overall outcome
measures using a random-effects model with an inverse variance
method to determineweightedmean differences with 95% conﬁdence
intervals (CIs) for continuous variables and Mantel–Haenszel odds
ratios for all dichotomous outcome data. A p-value of 0.05 was used to
determine the level of statistical signiﬁcance. Quantiﬁcation of
heterogeneity was examined with I2 to measure the degree of total
variation across trials owing to heterogeneity and establish the
consistency of evidence. I2 values N50% indicate a substantial level of
heterogeneity; if heterogeneity was observed, this was accommodat-
ed using a random-effect model. All descriptive statistical analyses
were carried out using SAS®. The meta-analysis was carried out using
RevMan 5.1.
3. Results
A total of 665 patients were treated with lixisenatide plus basal
insulin, and 533 patients were administered placebo plus basal
insulin. A summary of the results of each of the studies included is
shown in Supplementary Table 1. Patient demographics and clinical
characteristics in this meta-analysis were comparable in the lixisena-
tide and placebo groups (Table 1). At baseline, 84% of patients in each
treatment arm were receiving OADs. In violation of the respective
study protocols, eight patients in GetGoal-L (ﬁve patients in the
lixisenatide arm and three patients in the placebo arm) and two
patients in GetGoal-L-Asia (both in the placebo arm) received premix
insulin instead of basal insulin prior to screening.
3.1. Primary endpoint
Lixisenatide 20 μg once daily as add-on to basal insulin signiﬁ-
cantly reduced HbA1c from baseline to week 24 compared with
placebo plus basal insulin (p = 0.003; Fig. 1). The potential
heterogeneity for the primary endpoint was high (I2 = 90%), but
this was accommodated using a random-effects model.
3.2. Secondary endpoints
Patients treated with lixisenatide plus basal insulin were almost
four times more likely to achieve HbA1c b7% than patients who were
administered placebo plus basal insulin (HbA1c b7% in 39.0% vs. 21.0%
of patients, respectively; odds ratio [OR]: 3.67; p = 0.0016). In
patients who were insulin-naïve at the start of lixisenatide treatment,
lixisenatide plus basal insulin resulted in signiﬁcantly greater
reductions in HbA1c at week 24 compared with placebo plus basal
insulin (mean [SD] reductions of −0.60 [0.77]% and −0.30 [0.80]%,
respectively; p b 0.0001; Table 2). Compared with insulin-naïve
patients, reductions in HbA1c at week 24 with lixisenatide treatment
were greater in patients who were taking basal insulin at baseline
(mean [SD] reduction with lixisenatide plus basal insulin, −0.72[1.13]% versus placebo plus basal insulin,−0.11 [0.93]%, respectively;
p b 0.0001; Table 2). Lixisenatide plus basal insulin treatment
resulted in signiﬁcant improvement in HbA1c regardless of whether
or not patients were receiving concomitant sulfonylureas. Mean (SD)
week 24 HbA1c changes from baseline in the sulfonylurea-treated
patients were −0.91 (1.36)% with lixisenatide plus basal insulin and
0.04 (0.88)% with placebo plus basal insulin (p b 0.0001; Table 2). In
patients who were not receiving concomitant sulfonylureas, mean
(SD) HbA1c changes from baseline were −0.64 (0.95)% and −0.25
(0.87)%, respectively (p b 0.0001; Table 2).
Compared with placebo plus basal insulin, lixisenatide plus basal
insulin signiﬁcantly improved control of 2-hour PPG over 24 weeks
(p b 0.0001; Fig. 2A). Change in FPG at 24 weeks was not signiﬁcantly
different in the two treatment groups (Fig. 2B). Change with
lixisenatide plus basal insulin was −0.24 mg/dL compared with
+3.54 mg/dL for placebo plus basal insulin; p = NS).
Lixisenatide plus basal insulin signiﬁcantly reduced body mass
index by 0.26 kg/m2 compared with an increase of 0.12 kg/m2 with
placebo plus basal insulin (p b 0.0001). Mean body weight loss was
0.83 kg greater with lixisenatide plus basal insulin compared with
placebo plus basal insulin (p = 0.001; Fig. 2C).
Basal insulin dose by weight was signiﬁcantly lower at week 24
with lixisenatide plus basal insulin compared with placebo plus basal
insulin (−0.02 U/kg, 95% CI: −0.03, −0.01; p b 0.0001). At study
end, themean absolute change from baseline in basal insulin dose was
−0.57 U for lixisenatide plus basal insulin and 2.42 U for placebo plus
basal insulin (p b 0.0001).
3.3. Safety endpoints
Symptomatic hypoglycemia was signiﬁcantly more common in
patients treated with lixisenatide plus basal insulin than in patients
treated with placebo plus basal insulin (OR: 1.82; 95% CI: 1.29, 2.57;
Study or subgroup
GetGoal-Duo1
GetGoal-L
GetGoal-L-Asia
Mean
–0.598
–0.632
–0.895
SD
0.77
1.075
1.225
Total
215
304
146
Mean
–0.302
–0.242
0.023
SD
0.801
0.981
0.847
Total
221
158
154
Weight
35.0%
33.4%
31.6%
Mean difference
IV, Random, 95% CI
–0.30 [–0.44, –0.15]
–0.39 [–0.58, –0.20]
–0.92 [–1.16, –0.68]
PlaceboLixisenatide Mean difference
IV, Random, 95% CI
Total (95% CI) 665 533 100.0% –0.52 [–0.87, –0.18]
Favors lixisenatide Favors placebo
–2 –1 0 1 2Heterogeneity: Tau
2
 = 0.08; Chi2 = 19.21, df = 2 (p < 0.0001); I2 = 90%
Test for overall effect: Z = 3.00 (p = 0.003)
Fig. 1. Forest plot for meta-analysis of least squares mean difference between lixisenatide plus basal insulin and placebo plus basal insulin in terms of change in HbA1c—ITT
population. CI, conﬁdence interval; df, degrees of freedom; HbA1c, glycated hemoglobin; ITT, intent to treat; IV, inverse variance; SD, standard deviation.
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lixisenatide plus basal insulin and placebo plus basal insulin groups,
respectively, developed symptomatic hypoglycemia. Therewasanumerically
higher rate of severe hypoglycemia in patients treated with lixisenatide plus
basal insulin when comparedwith patients whowere administered placebo
plus basal insulin (5/665 [0.8%] and 0/533 patients, respectively).
Overall, 44/103 (42.7%) patients treated with a sulfonylurea and
lixisenatide plus basal insulin experienced symptomatic hypoglycemia
compared with 21/109 (19.3%) patients who were not treated with
lixisenatide (p b 0.001). In those who were not administered a
sulfonylurea (but were treated with basal insulin ± metformin ± a
thiazolidinedione), 138/562 (24.6%) patients and 70/424 (16.5%) patients
experienced symptomatic hypoglycemia in the lixisenatide and placebo
groups, respectively (p b 0.01). No patients who were being treated
concomitantly with a sulfonylurea experienced severe hypoglycemia.
Overall, 5/562 (0.9%) non-sulfonylurea treated patients in the lixisenatide
plus basal insulin group experienced severe hypoglycemia (versus no
patients receiving placebo and basal insulin without a sulfonylurea).Table 2
HbA1c change from baseline to week 24 in subanalyses.
Subpopulation Lixisenatide +
basal insulin
Placebo +
basal insulin
p-value
versus
placebo
Insulin-naïve at start
of lixisenatide treatment
n 215 221
Mean (SD) baselineHbA1c, % 7.56 (0.54) 7.60 (0.54)
Week24mean(SD)HbA1c,% 6.96 (0.81) 7.30 (0.85)
Mean (SD) HbA1c change
from baseline, %
−0.60 (0.77) −0.30 (0.80) b 0.0001
Non-insulin-naïve at start
of lixisenatide treatment
n 450 310
Mean (SD) baselineHbA1c, % 8.44 (0.82) 8.46 (0.81)
Week24mean(SD)HbA1c,% 7.72 (1.20) 8.35 (1.14)
Mean (SD) HbA1c change
from baseline, %
−0.72 (1.13) −0.11 (0.93) b 0.0001
Concomitant sulfonylurea use
n 103 109
Mean (SD) baselineHbA1c, % 8.58 (0.72) 8.61 (0.77)
Week24mean(SD)HbA1c,% 7.67 (1.34) 8.65 (1.13)
Mean (SD) HbA1c change
from baseline, %
−0.91 (1.36) 0.04 (0.88) b 0.0001
No concomitant sulfonylurea use
n 562 424
Mean (SD) baselineHbA1c, % 8.08 (0.85) 7.97 (0.78)
Week24mean(SD)HbA1c,% 7.44 (1.10) 7.72 (1.08)
Mean (SD) HbA1c change
from baseline, %
−0.64 (0.95) −0.25 (0.87) b 0.0001
HbA1c, glycated hemoglobin; SD, standard deviation.3.4. Composite endpoints
Patients in the lixisenatide plus basal insulin group were
signiﬁcantly more likely to achieve each of the composite endpoints
than patients who were administered placebo plus basal insulin.
Patients treated with lixisenatide plus basal insulin were over three
times more likely to achieve HbA1c b7% and no weight gain (OR: 3.35;
95% CI: 1.66, 6.77; p = 0.0008) and more than 2.5 times more likely
to have HbA1c b7% and no symptomatic hypoglycemia (OR: 2.65; 95%
CI: 1.30, 5.38; p = 0.0007) compared with patients treated with
placebo plus basal insulin, after 24 weeks. Furthermore, patients in
the lixisenatide plus basal insulin group were over 2.5 times more
likely to have HbA1c b7%, no weight gain and no symptomatic
hypoglycemia (p = 0.0009; Fig. 3).
4. Discussion
This meta-analysis of over 1000 patients demonstrated that
lixisenatide 20 μg once daily in combination with basal insulin was
effective for the treatment of patients with T2DM inadequately
controlled on basal insulin with or without OADs. Compared with
placebo plus basal insulin, treatment with lixisenatide plus basal
insulin resulted in signiﬁcantly greater reductions in HbA1c alongside
signiﬁcant reductions from baseline in the absolute basal insulin dose
and the insulin dose by weight given at the end of 24 weeks of
treatment. Lixisenatide plus basal insulin also signiﬁcantly improved
control of PPG and resulted in signiﬁcant weight loss when compared
with patients who were administered placebo plus basal insulin.
Reductions in HbA1c with lixisenatide treatment were robust and
were found to be signiﬁcant versus placebo in patients who: were
receiving basal insulin at the start of lixisenatide treatment; initiated
basal insulin with lixisenatide treatment; were receiving concomitant
sulfonylureas; or who were not receiving concomitant sufonylureas.
Importantly, patients who received lixisenatide plus basal insulin
were signiﬁcantly more likely than patients in the placebo group to
achieve all of the composite endpoints assessed. It would appear that
it is the magnitude of the reductions in body weight and the increased
likelihood of achieving glycemic control with lixisenatide plus basal
insulin that are driving the response in the composite endpoints in
this meta-analysis, compensating for the increased occurrence of
symptomatic hypoglycemia.
Symptomatic hypoglycemia was signiﬁcantly more common in
patients treated with lixisenatide plus basal insulin than in patients
treated with placebo plus basal insulin (27.4% vs. 17.1%). Previous
evidence has shown that the incidence of symptomatic hypoglycemia
with lixisenatide monotherapy is less than 2% (Fonseca et al., 2012),
while the combination of lixisenatide with sulfonylureas and/or
insulin markedly increases its incidence (to between 15 and 43%)
(Riddle, Aronson, Home, et al., 2013; Riddle, Forst, Aronson, et al.,
2013; Seino et al., 2012; Rosenstock, Hanefeld, Shamanna, et al.,
2014). Similar results have been reported for exenatide in
Study or
subgroup
GetGoal-Duo1
GetGoal-L
GetGoal-L-Asia
Mean
–56.671
–97.306
–148.272
SD
91.081
103.719
102.419
Total
194
235
131
Mean
3.331
–20.274
–6.636
SD
80.763
73.811
71.537
Total
204
123
142
Weight
33.7%
33.4%
32.9%
Mean difference
IV, Random, 95% CI
–60.00 [–76.95, –43.06]
–77.03 [–95.63, –58.43]
–141.64 [–162.76, –120.52]
PlaceboLixisenatide Mean difference
IV, Random, 95% CI
Total (95% CI) 560 469 100.0% –92.54 [–138.99, –46.09]
Favors lixisenatide Favors placebo
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Fig. 2. Forest plots for lixisenatide versus placebo in terms of (A) change in PPG, (B) change in FPG and (C) change in weight—ITT population. CI, conﬁdence interval; df, degrees of
freedom; FPG, fasting plasma glucose; ITT, intent to treat; IV, inverse variance; PPG, post-prandial plasma glucose; SD, standard deviation.
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et al., 2004; Buse, Bergenstal, Glass, et al., 2011; Gao, Yoon, Chuang,
et al., 2009). The present analysis pooled cohorts of different
ethnicities, with one of the trials being performed across multiple
countries in Asia (GetGoal-L-Asia). As shown in Supplementary
Table 1, the majority of patients participating in GetGoal-L-AsiaStudy or
subgroup
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Fig. 3. Forest plot for meta-analysis of likelihood of patients achieving HbA1c b7%, no we
df, degrees of freedom; HbA1c, glycated hemoglobin; ITT, intent to treat; M–H, Mantel–Haewere treated concomitantly with sulfonylureas, had longer disease
duration and lower body mass index at baseline compared with
patients in the other studies analyzed. Furthermore, patients in
GetGoal-L-Asia experienced greater reductions in HbA1c but less body
weight loss compared with patients from the other trials. This should
be taken into account when interpreting the results of this meta-ht
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the primary endpoint). In pooling substantially different cohorts,
treatment effects may be diluted or exaggerated. Indeed, the rate of
symptomatic hypoglycemia experienced by patients receiving con-
comitant sulfonylureas in GetGoal-L-Asia appears to have skewed
the occurrence of hypoglycemia in the meta-analysis as a whole. A
sub-analysis of patients treated concomitantly with sulfonylureas
(i.e. most of the patients in GetGoal-L-Asia versus the rest of the
meta-analysis population) indicated that rates of symptomatic
hypoglycemia rose by 18% when sulfonylureas were added to the
regimen, although no patients in this group experienced severe
hypoglycemia. Sulfonylurea treatment is associated with an in-
creased risk of hypoglycemia (Bodmer, Meier, Krahenbuhl, et al.,
2008) and in the recent European Public Assessment Report of
lixisenatide, it was concluded that hypoglycemia with lixisenatide
was mainly seen in patients who were treated concomitantly with a
sulfonylurea and/or basal insulin. For this reason, use of a sulfonylurea
and basal insulin simultaneously in patients treated with lixisenatide
was not recommended (European Medicines Agency). As noted above,
the results with lixisenatide plus basal insulin for the composite
endpoints indicated that patients were still signiﬁcantly more likely
to reach HbA1c targets without experiencing hypoglycemia than were
patients who received placebo plus basal insulin.
In this meta-analysis, treatment with lixisenatide plus basal
insulin did not result in signiﬁcant improvements over placebo plus
basal insulin in terms of reductions in FPG. However, the addition
of lixisenatide to basal insulin resulted in signiﬁcant improvements
compared with placebo in terms of PPG control. Many patients with
T2DM who achieve FPG control experience large PPG excursions
(Avignon, Radauceanu, & Monnier, 1997; Bouma, Dekker, de Sonnaville,
et al., 1999; Soonthornpun, Rattarasarn, Leelawattana, et al., 1999;Verges,
2002) and there is, therefore, a strong clinical rationale for combining a
treatment that addresses FPG (basal insulin) with a treatment that
effectively controls PPG (e.g. a prandial GLP-1 RA, prandial insulin, or a
DPP-4 inhibitor). The differing effects of lixisenatide on FPG and PPG
are also observed for twice-daily exenatide and can be explained by
the short-acting pharmacokinetic proﬁle of these two agents (Meier,
2012). A head-to-head study comparing prandial GLP-1 RA therapy
with once-daily lixisenatide versus twice-daily exenatide in patients
uncontrolled on metformin demonstrated comparable reductions
in HbA1c and FPG in each group, although PPG levels were not
reported. Mean weight loss was slightly higher with exenatide
versus lixisenatide, but the incidence of symptomatic hypoglycemia
and gastrointestinal adverse events was signiﬁcantly lower with
lixisenatide versus exenatide (Rosenstock, Raccah, Korányi, et al.,
2013). A 4-week, pharmacodynamic study comparing prandial
short-acting lixisenatide versus long-acting liraglutide in patients
inadequately controlled on metformin further highlights the clinical
consequences of GLP-1 RA pharmacokinetics (Kapitza, Forst,
Coester, et al., 2013). The reduction in PPG with lixisenatide was
signiﬁcantly greater than with liraglutide, while the reduction in
FPG with liraglutide was signiﬁcantly greater than with lixisenatide.
Overall, HbA1c and body-weight reductions were slightly greater
with liraglutide versus lixisenatide, the incidence of gastrointestinal
events was slightly lower with lixisenatide versus liraglutide, and
there were no reported events of symptomatic hypoglycemia in
either group. Preliminary data have also recently been made
available for an 8-week pharmacodynamic study comparing addition
of lixisenatide versus liraglutide in patients not optimally controlled
following systematic titration of insulin glargine (Meier, Rosenstock,
Hincelin-Méry et al). PPG reductions were signiﬁcantly greater with
lixisenatide versus liraglutide, while clinically comparable reduc-
tions in HbA1c were seen across the treatment groups. Symptomatic
hypoglycemia was slightly more frequent with lixisenatide, and
patients receiving liraglutide experienced more lower gastrointes-
tinal tract events.A number of prandial agents other than GLP-1 RAs have been
shown to be effective in achieving HbA1c targets when given in
combination with basal insulin in patients with T2DM (Buse et al.,
2011; Arnolds, Dellweg, Clair, et al., 2010; Leahy, 2012; Nayak,
Govindan, Baskar, et al., 2010; Owens, Luzio, Sert-Langeron, et al.,
2011; Riddle & Rosenstock, 2003; Rosenstock, Rodbard, Bain, et al.,
2013). In patients with T2DM who are insufﬁciently controlled on
basal insulin, treatment intensiﬁcation with an RAI is commonly
recommended for control of post-prandial hyperglycemia (Garber
et al., 2013; Inzucchi et al., 2012). Results of the 4T study reported that
approximately two-thirds of patients who received a basal–prandial
insulin regimen, subsequent to loss of glycemic control on basal
insulin plus OADs, achieved a target HbA1c of b7% (Holman et al.,
2009). However, while treatment intensiﬁcation with prandial insulin
can effectively reduce HbA1c, pre-mixed insulin, basal–bolus and
basal-plus regimens are associated with hypoglycemia and weight
gain, resulting in poor treatment acceptance and compliance issues as
a consequence of side effects and dosing complexity (Russell-Jones &
Khan, 2007; Bonafede, Kalsekar, Pawaskar, et al., 2011; Farrokhi,
Klindukhova, Chandra, et al., 2012; Odegard & Capoccia, 2007).
Moreover, these side effects of hypoglycemia and weight gain are
likely to be particularly impactful in elderly, frail, or obese patients.
GLP-1 RAs have demonstrable beneﬁts in terms of weight loss.
Effect on weight is an important consideration when selecting the
most appropriate treatments to achieve glycemic control in T2DM.
Patients are often unwilling to commence or intensify insulin-based
treatments owing to associatedweight gain. Treatment intensiﬁcation
with GLP-1 RAsmay, therefore, present a useful alternative to prandial
insulin in patients insufﬁciently controlled on basal insulin.
Indeed, recent results from the 4B study have indicated that HbA1c
reductions with twice-daily exenatide plus insulin glargine were non-
inferior to those observed with mealtime bolus insulin lispro plus
insulin glargine. Moreover, FPG and body weight were signiﬁcantly
lower, and the annualized rate of hypoglycemic events was reduced
with exenatide plus insulin glargine (Diamant, Nauck, Shaginian,
et al). GetGoal-Duo2, a study comparing lixisenatide once daily plus
insulin glargine with the RAI insulin glulisine once or thrice daily plus
insulin glargine, is ongoing with an estimated completion date of
December 2014.
The ﬁndings of the current meta-analysis demonstrate that
lixisenatide plus basal insulin is a favorable option for treatment
intensiﬁcation in patients with T2DM insufﬁciently controlled with
basal insulin alone, as these agents have complementary effects on
PPG and FPG, respectively. Evidence from the GetGoal-Duo1 study
indicates that addition of lixisenatide can be beneﬁcial within
12 weeks of basal insulin initiation for patients with HbA1c N7%
despite basal insulin being titrated systematically to control FPG
levels (Riddle, Forst, Aronson, et al., 2013). Patients on basal insulin
experiencing marked PPG excursions may beneﬁt most from the
addition of lixisenatide and future studies should investigate this
and other potential identiﬁers of lixisenatide response to guide
clinical decisions.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jdiacomp.2014.07.007.
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